(PharmaNewsWire.Com, March 04, 2017 ) According to Publisher, the Veterinary Anti-infectives market is accounted for $4.79 billion in 2015 and is expected to reach $9.11 billion by 2022 growing at a CAGR of 9.6% from 2015 to 2022. Growing zoonotic and foodborne diseases and greater livestock production are the key factors fueling the market growth. Increased competition for cultivated land and cost effective production are the major factors that are hampering the market growth. On the other hand, with constant innovation and quick technological advancements, the probability of decreasing the cost of anti-infective drugs is high.
Some of the key players in the market include Novartis Animal Health, Inc., Virbac, Boehringer Ingelheim, Zoetis, Ceva Animal Health, Bayer healthcare, Heska Corporation, Merial Animal Health, Bioniche Animal Health Canada, Inc., Merck & Co., Inc.,Sanofi-Aventis, Pfizer Inc. and Elanco.
Regions Covered: -North America -US -Canada -Mexico -Europe -Germany -France -Italy -UK -Spain -Rest of Europe -Asia Pacific -Japan -China -India -Australia -New Zealand -Rest of Asia Pacific -Rest of the World -Middle East -Brazil -Argentina -South Africa -Egypt
9 Company Profiling 9.1 Novartis Animal Health, Inc. 9.2 Virbac 9.3 Boehringer Ingelheim 9.4 Zoetis 9.5 Ceva Animal Health 9.6 Bayer healthcare 9.7 Heska Corporation 9.8 Merial Animal Health 9.9 Bioniche Animal Health Canada, Inc. 9.10 Merck & Co., Inc., 9.11 Sanofi-Aventis 9.12 Pfizer Inc. 9.13 Elanco
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
